Zoledronate Effects on Systemic and Jaw Osteopenias in Ovariectomized Periostin-Deficient Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bonnet, Nicolas ^a   Lesclous, Philippe ^b,c   Saffar, Jean Louis ^b   Ferrari, Serge ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b France   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX2; ZOLEDRONIC ACID;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MASS; BONE NECROSIS; BONE REMODELING; BONE TURNOVER; CELL COUNT; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENOTYPE; HISTOPATHOLOGY; IN VIVO STUDY; JAW DISEASE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOPENIA; OVARIECTOMY; PERIODONTAL DISEASE; SYSTEMIC DISEASE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; CELL ADHESION MOLECULES; DIPHOSPHONATES; FEMALE; IMIDAZOLES; JAW; MICE; MICE, KNOCKOUT; OVARIECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84874705692     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058726     Document Type: Article

References (72)

1. Albandar JM, Kingman A, (1999) Gingival recession, gingival bleeding, and dental calculus in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 70: 30-43.
2. Lerner UH, (2006) Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis. J Dent Res 85: 596-607.
3. Koduganti RR, Gorthi C, Reddy PV, Sandeep N, (2009) Osteoporosis: 'A risk factor for periodontitis'. J Indian Soc Periodontol 13: 90-96.
4. Wactawski-Wende J, (2001) Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol 6: 197-208.
5. Tezal M, Wactawski-Wende J, Grossi SG, Dmochowski J, Genco RJ, (2005) Periodontal disease and the incidence of tooth loss in postmenopausal women. J Periodontol 76: 1123-1128.
6. Wactawski-Wende J, Grossi SG, Trevisan M, Genco RJ, Tezal M, et al. (1996) The role of osteopenia in oral bone loss and periodontal disease. J Periodontol 67: 1076-1084.
7. Duarte PM, de Assis DR, Casati MZ, Sallum AW, Sallum EA, et al. (2004) Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol 75: 1196-1202.
8. El-Shinnawi UM, El-Tantawy SI, (2003) The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 5: 5-10.
9. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, et al. (2005) Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 76: 1113-1122.
10. Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A, (2007) Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 9: 70-76.
11. Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME, (2004) Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol 75: 1579-1585.
12. Rocha M, Nava LE, Vázquez de la Torre C, Sánchez-Márin F, Garay-Sevilla ME, et al. (2001) Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol 72: 204-209.
13. Leonard EP, Reese WV, Mandel EJ, (1979) Comparison of the effects of ethane-1-hydroxy-1,1-diphosphonate and dichloromethylene diphosphonate upon periodontal bone resorption in rice rats (Oryzomys palustris). Arch Oral Biol 24: 707-708.
14. Gotcher JE, Jee WS, (1981) The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies. J Periodontal Res 16: 275-291.
15. Shoji K, Horiuchi H, Shinoda H, (1995) Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res 30: 277-284.
16. Mitsuta T, Horiuchi H, Shinoda H, (2002) Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis. J Periodontol 73: 479-486.
17. Alencar VB, Bezerra MM, Lima V, Abreu AL, Brito GA, et al. (2002) Disodium chlodronate prevents bone resorption in experimental periodontitis in rats. J Periodontol; () 73: 251-256.
18. Tani-Ishii N, Minamida G, Saitoh D, Chieda K, Omuro H, et al. (2003) Inhibitory effects of incadronate on the progression of rat experimental periodontitis by porphyromonas gingivalis infection. J Periodontol 74: 603-609.
19. Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, et al. (1994) Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 29: 35-40.
20. Bilezikian JP, (2006) Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 355: 2278-2281.
21. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, et al. (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42: 841-847.
22. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491.
23. Hoff AO, Toth BB, Altuntag K, Johnson MM, Warnecke CL, et al. (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826-836.
24. Dental management of patients receiving oral bisphosphonate therapy: expert.
25. panel recommendations. J Am Dent Assoc 137: 1144-1150.
26. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, et al. (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20: 117-120.
27. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, et al. (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. Ann Oncol 20: 137-145.
28. Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, et al. (2011) Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 26: 1871-1882.
29. Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, et al. (2012) Oncologic doses of Zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (oryzomys palustris) with periodontitis. J Bone Miner Res in press.
30. Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, et al. (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45: 843-852.
31. Reid IR, Cornish J, (2011) Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8: 90-96.
32. Norris RA, Damon B, Mironov V, Kasyanov V, Ramamurthi A, et al. (2007) Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 101: 695-711.
33. Rani S, Barbe MF, Barr AE, Litvin J, (2009) Periostin-like-factor and Periostin in an animal model of work-related musculoskeletal disorder. Bone 44: 502-512.
34. Rios H, Koushik SV, Wang H, Wang J, Zhou HM, et al. (2005) periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25: 11131-11144.
35. Bonnet N, Standley KN, Bianchi EN, Stadelmann V, Foti M, et al. (2009) The matricellular protein Periostin is required for Sclerostin inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem 284: 35939-35950.
36. Van Poznak CH, Von Roenn JH, Temin S, (2011) American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract 7: 117-121.
37. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR, (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23: 544-551.
38. Sheng ZF, Xu K, Ma YL, Liu JH, Dai RC, et al. (2009) Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. Osteoporos Int 20: 151-159.
39. Huja SS, Fernandez SA, Phillips C, Li Y, (2009) Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch Oral Biol 54: 851-856.
40. Iida-Klein A, Lu SS, Yokoyama K, Dempster DW, Nieves JW, et al. (2003) Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. J Clin Densitom 6: 25-33.
41. Bouxsein ML, Pierroz DD, Glatt V, Goddard DS, Cavat F, et al. (2005) beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 20: 635-643.
42. Hildebrand T, Ruegsegger P, (1997) A new method for the model-independent assessment of thickness in the three-dimensional images. Journal of Microscopy 185: 67-75.
43. Chappard D, Palle S, Alexandre C, Vico L, Riffat G, (1987) Bone embedding in pure methyl methacrylate at low temperature preserves enzyme activities. Acta Histochem 81: 183-190.
44. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610.
45. Lasfargues JJ, Saffar JL, (1993) Inhibition of prostanoid synthesis depresses alveolar bone resorption but enhances root resorption in the rat. Anat Rec 237: 458-465.
46. McMillan PJ, Dewri RA, Joseph EE, Schultz RL, Deftos LJ, (1989) Rapid changes of light microscopic indices of osteoclast-bone relationships correlated with electron microscopy. Calcif Tissue Int 44: 399-405.
47. Turner CH, Burr DB, (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14: 595-608.
48. Bonnet N, Conway SJ, Ferrari SL, (2012) Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci U S A 109: 15048-15053.
49. Pihlstrom BL, Michalowicz BS, Johnson NW, (2005) Periodontal diseases. Lancet 366: 1809-1820.
50. Allen MR, Kubek DJ, Burr DB, Ruggiero SL, Chu TM, (2011) Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int 22: 693-702.
51. Abtahi J, Agholme F, Sandberg O, Aspenberg P, (2012) Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone. J Oral Pathol Med In press.
52. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC, (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45: 164-172.
53. Allen MR, Ruggiero SL, (2011) Osteonecrosis of the Jaw: Recent Clinical and Preclinical Advances. IBMS BoneKEy 8: 141-153.
54. Ravosa MJ, Ning J, Liu Y, Stack MS, (2011) Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol 56: 491-498.
55. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF, (2009) Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144: 667-676.
56. Cornish J, Bava U, Callon KE, Bai J, Naot D, et al. (2011) Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 49: 710-716.
57. Hansen T, Kunkel M, Weber A, James Kirkpatrick C, (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates- histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
58. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, et al. (2010) Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25: 606-616.
59. Russell RG, Watts NB, Ebetino FH, Rogers MJ, (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733-759.
60. Yu YY, Lieu S, Hu D, Miclau T, Colnot C, (2012) Site Specific Effects of Zoledronic Acid during Tibial and Mandibular Fracture Repair. PLoS One 7: e31771.
61. Mavropoulos A, Rizzoli R, Ammann P, (2007) Different responsiveness of alveolar and tibial bone to bone loss stimuli. J Bone Miner Res 22: 403-410.
62. Masarachia P, WeinrebM, Balena R, Rodan GA, (1996) Comparison of the distribution of 3Halendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281-290.
63. Cremers S, Papapoulos S, (2011) Pharmacology of bisphosphonates. Bone 49: 42-49.
64. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, et al. (2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36: 2043-2049.
65. Bauss F, Pfister T, Papapoulos S, (2008) Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 26: 406-408.
66. Contié S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, et al. (2010) Development of a New ELISA for Serum Periostin: Evaluation of Growth-Related Changes and Bisphosphonate Treatment in Mice. Calcif Tissue Int 87: 341-350.
67. Merle B, Garnero P, (2012) The multiple facets of periostin in bone metabolism. Osteoporos Int In press.
68. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, et al. (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118: 98-104.
69. Padial-Molina M, Volk SL, Taut AD, Giannobile WV, Rios HF, (2012) Periostin is Down-regulated during Periodontal Inflammation. J Dent Res In press.
70. Rios HF, Ma D, Xie Y, Giannobile WV, Bonewald LF, et al. (2008) Periostin Is Essential for the Integrity and Function of the Periodontal Ligament During Occlusal Loading in Mice. J Periodontol 79: 1480-1490.
71. Ma D, Lu H, Xu L, Xu X, Xiao W, (2009) Mechanical loading promotes Lewis lung cancer cell growth through periostin. In Vitro Cell Dev Biol Anim 45: 467-472.
72. Ouyang G, Liu M, Ruan K, Song G, Mao Y, et al. (2009) Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett 281: 213-219.